@article{5282c2d974ae44f5921b4c05b712fd28,
title = "Salivary antibody responses to ten-valent pneumococcal conjugate vaccination following two different immunization schedules in a healthy birth cohort",
abstract = "Pneumococcal conjugate vaccines reduce pneumococcal colonization via serotype-specific immunoglobulin G (IgG) at mucosal surfaces. The infant immunization schedule with the ten-valent pneumococcal conjugate vaccine (PCV10) changed from a 3 + 1 schedule (2–3-4–11 months) to a 2 + 1 schedule (2–4–11 months) in The Netherlands in 2013. We compared anti-pneumococcal IgG concentrations in saliva between the schedules. IgG was measured using a fluorescent bead-based multiplex immunoassay at the ages of 6 (post-primary) and 12 (post-booster) months in 51 infants receiving the 3 + 1 schedule and 68 infants receiving the 2 + 1 schedule. Post-primary IgG geometric mean concentrations (GMCs) were comparable between schedules for all vaccine serotypes. Post-booster IgG GMCs were significantly lower after the 2 + 1 schedule for serotypes 4 (p = 0.035), 7F (p = 0.048) and 23F (p = 0.0056). This study shows small differences in mucosal IgG responses between a 3 + 1 and a 2 + 1 PCV10 schedule. Future studies should establish correlates of protection against pneumococcal colonization for mucosal antibodies.",
keywords = "immunoglobulin G, Infant, Mucosal immunity, PCV10, Vaccination schedule",
author = "{de Koff}, {Emma M.} and {van Houten}, {Marlies A.} and {de Heij}, Femke and Berbers, {Guy A.M.} and Debby Bogaert and Sanders, {Elisabeth A.M.}",
note = "Funding Information: We are indebted to all participants of the Microbiome Utrecht Infant Study and their parents. We also thank the research team of the Spaarne Gasthuis Academy (Hoofddorp, NL) and the staff of the Streeklaboratorium Haarlem (Haarlem, NL) for their efforts. This work was supported by the Netherlands Organization for Scientific Research (grant number 91715359), Chief Scientist Office/NHS Research Scotland (SCAF/16/03), Spaarne Gasthuis, Dutch Ministry of Health, Welfare and Sport and the Strategic Program of the National Institute for Public Health and the Environment (SPR). The funding sources had no involvement in the study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. Funding Information: This work was supported by the Netherlands Organization for Scientific Research (grant number 91715359), Chief Scientist Office/NHS Research Scotland (SCAF/16/03), Spaarne Gasthuis, Dutch Ministry of Health, Welfare and Sport and the Strategic Program of the National Institute for Public Health and the Environment (SPR). The funding sources had no involvement in the study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. Publisher Copyright: {\textcopyright} 2021 The Authors",
year = "2022",
month = jan,
day = "24",
doi = "10.1016/j.vaccine.2021.12.013",
language = "English",
volume = "40",
pages = "408--413",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier",
number = "3",
}